Regeneron Pharmaceuticals, Inc.
Traded as NASDAQ: REGN
NASDAQ-100 Component
S&P 500 Component
Industry Pharmaceuticals; Biotech
Founded 1988
Headquarters Tarrytown, New York, US (Headquarters)
Area served
Key people
Revenue Increase $4.1 billion[1]
Increase $1.4 billion[1]
Total assets Increase $5.6 billion[1]

Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988.[2] Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

Company history

Regeneron has two products in development based on aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation. On March 26, 2012 Bloomberg announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72% more than the leading brands. It is believed this new drug will greatly reduce heart disease in patients around the world. The medicine, one in a class of drugs targeting the PCSK9 gene, reduced patients’ average LDL cholesterol levels to as little as 34 milligrams per deciliter after 12 weeks in the mid- stage study, presented on March, 2012 at the American College of Cardiology meeting in Chicago.

In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,[3] with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810.[4]

Marketed products

EYLEA (aflibercept injection): Approved by the U.S. Food and Drug Administration (FDA) in November 2011.[2][5] EYLEA developed to treat a common cause of blindness in the elderly.

ARCALYST (rilonacept) for specific, rare autoinflammatory conditions. Approved by the FDA in February 2008.

ZALTRAP (aflibercept injection) for metastatic colorectal cancer: Approved by the FDA in August 2012.[6]

PRALUENT (Alirocumab) indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. Approved by FDA on 24 July 2015 [7]

Technology platforms

Trap Fusion Proteins: Regeneron’s novel and patented Trap technology creates high-affinity product candidates for many types of signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin-G constant region.

Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.[8]:255-258

Financial performance

Financial Year Revenue Ref
2012 $1.4 billion [9]
2013 $2.1 billion [10]
2014 $2.8 billion [1]
2015 $4.1 billion [1]

See also


  1. 1 2 3 4 5
  2. 1 2 Herper, Matthew (August 14, 2013). "How Two Guys From Queens Are Changing Drug Discovery". Forbes. United States. Archived from the original on March 16, 2014. Retrieved March 22, 2014.
  3. "Regeneron, Sanofi Launch $2B+ Immuno-Oncology Collaboration - GEN News Highlights - GEN".
  4. "UPDATED: Struggling Sanofi paying $1.8B to partner with Regeneron on immuno-oncology - FierceBiotech".
  5. "Regulators Approve a Drug for an Eye Condition". The New York Times. Associated Press. November 18, 2011.(registration required)
  6. "FDA approves Zaltrap for metastatic colorectal cancer" (Press release). U.S. Food and Drug Administration. August 3, 2012. Archived from the original on June 25, 2013.
  8. Susana Magadán Mompó and África González-Fernández. Human Monoclonal Antibodies from Transgenic Mice. Chapter 13 in Human Monoclonal Antibodies: Methods and Protocols Ed. Michael Steinitz. Springer Science+Business Media, 2014. ISBN 978-1-62703-585-9
  9. "REGENERON PHARMACEUTICALS INC 2013 Annual Report Form (10-K)" (XBRL). United States Securities and Exchange Commission. February 13, 2014.
  10. "REGENERON PHARMACEUTICALS INC 2013 Annual Report Form (10-K)" (XBRL). United States Securities and Exchange Commission. February 13, 2014.

External links

This article is issued from Wikipedia - version of the 11/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.